Prediction of Amyloid-β pathology in amnestic mild cognitive impairment with neuropsychological tests
Assessment of disease biomarkers, particularly the in vivo assessment of amyloid-β (Aβ) burden with positron emission tomography (PET), is gradually becoming central to the diagnosis of mild cognitive impairment (MCI) due to Alzheimer's disease (AD). Ho
|Collections||ANU Research Publications|
|Source:||Journal of Alzheimer's Disease|
|01_Bahar-Fuchs_Prediction_of_Amyloid-β_2013.pdf||303.16 kB||Adobe PDF||Request a copy|
Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.